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  ♦ Background: Little is known about the prevalence of functional 
impairment in peritoneal dialysis (PD) patients, its variation by coun-
try, and its association with mortality or transfer to hemodialysis.  
  ♦ Methods: A prospective cohort study was conducted in PD 
patients from 7 countries in the Peritoneal Dialysis Outcomes and 
Practice Patterns Study (PDOPPS) (2014 – 2017). Functional status 
(FS) was assessed by combining self-reports of 8 instrumental and 
5 basic activities of daily living, using the Lawton-Brody and the 
Katz questionnaires. Summary FS scores, ranging from 1.25 (most 
dependent) to 13 (independent), were based on the patient’s abil-
ity to perform each activity with or without assistance. Logistic 
regression was used to estimate the odds ratio (OR; 95% confi-
dence interval [CI]) of a FS score < 11 comparing each country 
with the United States (US). Cox regression was used to estimate 
the hazard ratio (HR; 95% CI) for the effect of a low FS score on 
mortality and transfer to hemodialysis, adjusting for case mix.
  ♦ Results: Of 2,593 patients with complete data on FS, 48% were 
fully independent (FS = 13), 32% had a FS score 11 to < 13, 14% 
had a FS score 8 to < 11, and 6% had a FS score < 8. Relative to the 
US, low FS scores (< 11; more dependent) were more frequent in 
Thailand (OR = 10.48, 5.90 – 18.60) and the United Kingdom (UK) 
(OR = 3.29, 1.77 – 6.08), but similar in other PDOPPS countries. 
The FS score was inversely and monotonically associated with mor-
tality but not with transfer to hemodialysis; the HR, comparing a 
FS score < 8 vs 13, was 4.01 (2.44 – 6.61) for mortality and 0.91 
(0.58 – 1.43) for transfer to hemodialysis.   
  ♦ Conclusion: Regional differences in FS scores observed across 
PDOPPS countries may have been partly due to differences in regional 
patient selection for PD. Functional impairment was associated 
with mortality but not with permanent transfer to hemodialysis.
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Functional impairment is highly prevalent among dialysis patients and is associated with morbidity and mortality 
(1–8). Studies evaluating functional impairment based on 
the ability of patients to perform basic activities of daily living 
(ADLs) have demonstrated an association with mortality (7,9). 
More recently, investigators from the Dialysis Outcomes and 
Practice Patterns Study (DOPPS) identified a strong association 
between reduced functional status (FS) among hemodialysis 
(HD) patients (based on the ability of patients to perform ADLs 
ranging from 1.25 or most dependent to 13 or functionally 
independent) and death across participating countries (10). 
Patients receiving HD with high functional dependence (score 
of < 8) had a nearly 2.5-fold increase in the adjusted hazard 
ratio for mortality compared with those who could perform all 
13 ADLs without assistance (10). 
Although functional impairment appears to be a risk factor 
for poor outcomes among HD patients, much less is known 
about the prevalence and outcomes of impaired FS in peritoneal 
dialysis (PD). In general, PD patients are more independent, 
self-managing, and have home supports to facilitate dialysis. 
However, functional impairment in PD is still highly prevalent 
(ranging from 30% – 60%, using measures based on the ability 
to independently perform ADLs) (11–13), and it is associated 
with mortality in some studies (14,15).  
While informative, all previous studies done to esti-
mate the association between FS and outcomes among PD 
patients have been restricted to single centers or multiple 
centers in 1 region or country (11–15), ignoring possible 
differences in facilities and PD selection among regions and 
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countries. Furthermore, some of the previous studies focused 
predominantly on elderly patients but did not specifically 
evaluate functional impairment for younger individuals 
(11,13,15). Finally, studies to date have not examined the 
association between functional impairment and permanent 
transfer to HD. 
Therefore, in a cohort of patients across countries par-
ticipating in the Peritoneal Dialysis Outcomes and Practice 
Patterns Study (PDOPPS), the aims of this study were: 1) to 
estimate and compare the distribution of FS and the prevalence 
of impaired FS in PD patients across PDOPPS countries; and 
2) to estimate the associations between FS and all-cause mor-
tality and permanent transfer to HD, controlling for potential 
confounders. We hypothesized that there would be a high 
prevalence of functional impairment for the entire cohort, 
but a relatively higher proportion of functionally impaired 
patients within countries with well-established programs to 
provide assisted PD (e.g. the United Kingdom and Canada 
[11,16–18]). We also hypothesized that functional impairment 
would be associated with death and permanent transfer to HD, 
adjusting for differences in patient case mix. 
METHODS
DATA SOURCE AND VARIABLES
The PDOPPS is an international prospective cohort study 
in collaboration with the International Society for Peritoneal 
Dialysis (ISPD) (19). Patients ≥ 18 years of age receiving 
chronic PD are selected randomly from national samples of 
PD facilities. This analysis includes data from Australia/New 
Zealand, Canada, Japan, Thailand, the United Kingdom (UK), 
and the United States (US) in 2014 – 2017; countries joining 
PDOPPS more recently (Columbia and South Korea, to date) 
are not included. Study details are provided at https://www.
dopps.org/OurStudies/PeritonealDialysisPDOPPS.aspx (19). 
Data were collected using uniform and standardized data col-
lection tools, procedures, and processes implemented across 
the DOPPS Program. Data from patients receiving care at large 
dialysis organization (LDO) sites in the US were imported from 
electronic health records; data from all other PDOPPS patients 
were obtained from manual medical chart abstraction and 
entered into a web-based data collection tool. 
Functional status was assessed by combining responses to 
2 self-reported patient questionnaires: the Katz questionnaire 
(20), which evaluates a patient’s ability to perform each of 
5 basic ADLs (binary scale); and the Lawton-Brody question-
naire (21), which evaluates a patient’s ability to perform 8 
more advanced instrumental ADLs (IADLs; 3-category ordinal 
scale). We combined the 2 scales by rescaling the 13 item 
scores and summing to create an overall FS score, ranging 
from 1.25 (most functionally dependent) to 13 (functionally 
independent) (10,21). The FS score was categorized for differ-
ent analyses as either binary (< 11 [functionally impaired] vs 
≥ 11) or ordinal (< 8 [most functionally impaired], 8 to < 11, 11 
to < 13, and 13). The binary variable was used as the outcome 
when comparing countries, and the ordinal variable was 
treated as the main predictor of mortality and transfer to HD. 
Permanent transfer to HD was defined as deemed permanent 
transfers, or temporary transfers from PD to HD that did not 
return to PD within 12 weeks (84 days).
Potential confounders collected in the PDOPPS included 
demographics, comorbidities, laboratory variables, and 
PD-specific factors. Additionally, we capture quality of life 
using the SF-12 (a subset of the Kidney Disease Quality of 
Life-36 [22]) which was summarized into a physical compo-
nent summary score (PCS) and mental component summary 
score (MCS). 
Characteristics of study patients were summarized descrip-
tively and compared with the remaining sample (which included 
patients who did not return a FS questionnaire, patients who 
did not have complete data on FS, and those who transferred 
to HD prior to completion of a FS questionnaire). Differences 
in patient characteristics among patients were examined 
descriptively by FS score category. To compare the prevalence 
of functional impairment (FS score < 11) in each PDOPPS coun-
try, compared with the US, we used logistic regression with 
generalized estimating equations to estimate the prevalence 
odds ratio (OR) and 95% confidence interval (CI) for an FS score 
< 11 vs ≥ 11, assuming an exchangeable working correlation to 
account for clustering within facilities. Adjustment was made 
for the following covariates thought to be risk factors for FS 
(the outcome): age, sex, body mass index (BMI), 13 summary 
comorbid conditions (Table 1), prior amputation, serum albu-
min, hemoglobin level, dialysis vintage, an indicator (yes/no) 
of receipt of dialysis within a LDO in the US and PD-specific 
variables (automated vs continuous ambulatory PD, and time 
transport to PD facility).
Cox regression was used to estimate the association 
between FS and 3 time-to-event outcomes: all-cause mortal-
ity; permanent transfer to HD; and either death or permanent 
transfer to HD, whichever came first (a composite outcome). 
Proportionality was tested using weighted Schoenfeld residu-
als. Models were left-truncated, with time from study enroll-
ment to outcome event or censoring as the time axis and time 
at risk beginning at the patient questionnaire completion 
date. Models were stratified by country, accounting for facil-
ity clustering using robust sandwich covariance estimators, 
and adjusting for the same covariates listed above. Follow-up 
ended at the time of death, 7 days after leaving the facility due 
to transfer or change in renal replacement therapy modality, 
loss to follow-up, transplantation, end of study phase, or the 
most recent date of data availability (whichever occurred first). 
If a patient died within 7 days of permanent transfer to HD, 
this patient would be counted as both a permanent transfer 
to HD and death. Patients who died  8 – 84 days after transfer 
to HD were only counted as a permanent transfer to HD and 
not death. The median length of follow-up from patient ques-
tionnaire completion was 14.8 months (interquartile range 
[IQR]: 8.6 – 23.8 months).
We conducted an additional analysis excluding patients 
from Thailand. This was done because of anticipated differences 
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in results due to major differences in practice patterns around 
PD policy in Thailand compared with the other participating 
PDOPPS countries (23).
For primary analyses among the study patients, missing 
covariate values were imputed multiply using the Sequential 
Regression Multiple Imputation Method by IVEware (24). 
Results from 20 imputed data sets were combined for the final 
analysis using Rubin’s formula (25). The proportions of missing 
data were < 10% for all imputed covariates, with the exception 
of BMI (13% missing). All analyses used SAS software, version 
9.4 (SAS institute Inc., Cary, NC).
RESULTS
A total of 5,863 patients received a patient questionnaire 
regarding FS; 2,593 PD patients (44% of the entire cohort) were 
eligible for analysis after exclusions (Figure 1). The median 
time from study entry to completion of the FS questionnaire 
was 2 months (IQR 1 – 4). Most patient characteristics were 
similar between included and excluded patients. However, 
patients included in this analysis had longer end-stage renal 
disease (ESRD) vintage (median 1.7 vs 1.3 years) and lower 
BMI (mean 26.8 vs 28.2 kg/m2) compared with excluded 
patients. The adjusted HR for death, permanent transfer 
to HD, or the composite of death/permanent transfer to 
HD was not significantly different comparing included vs 
excluded patients (Supplemental Table 1). Characteristics of 
included and excluded patients for each PDOPPS participating 
country are summarized in Table 2. Although most character-
istics were similar, there was a higher prevalence of diabetes 
among excluded vs included patients for the overall cohort 
(49% vs 43%).  
TABLE 1 
Proportion of Patients Able to Complete Each Activity of Daily Living and Instrumental Activity of Daily Living Task  
in the Study Sample
Able to perform the task without assistance Ability to perform the task
Yes 
(1)
No 
(0.25)
Need no 
help (1)
Need some 
help (0.5)
Unable to do 
at all (0)
Activities of Daily Living (ADL)
Eating 98% 2%
Getting dressed 96% 4%
Bathing 93% 7%
Using the toilet 98% 2%
Transferring from bed to chair 98% 2%  
Instrumental Activities of Daily Living (IADL)
Using the telephone 94% 5% 2%
Getting places beyond walking distance 70% 22% 8%
Grocery shopping 72% 21% 7%
Preparing meals 77% 16% 7%
Doing housework or handyman work 57% 32% 11%
Doing laundry 74% 16% 10%
Taking medications 90% 8% 2%
Managing money 87% 9% 4%
DOPPS = Dialysis Outcomes and Practice Patterns Study; IADL = instrumental activities of daily living; ADL = activities of daily living.
Individual items and calculated summary scores were generated using the same approach as a previous DOPPS study evaluating functional 
impairment among hemodialysis patients (10). Specifically, IADL responses of “need no help” were scored 1; “need some help,” scored 0.5; and 
“unable to do at all,” scored 0.  Responses of “yes” to ADL were scored 1. Acknowledging that a response of “no” could not distinguish patients 
who were unable to perform a task or able to perform it with some help on the Katz questionnaire, a score of 0.25 was assigned rather than 0. 
Figure 1 — Patient flow diagram. ADL = activities of daily living; IADL = 
instrumental ADL.
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DISTRIBUTION OF FS SCORES
The distribution of ADL and IADL items among PD patients 
is shown in Table 1. The proportion of patients who could per-
form each task without assistance ranged from 98% (eating, 
using the toilet, and transferring from bed to chair) to 57% 
(doing housework or handyman work) (Table 1). Ninety-two 
percent of patients reported the ability to perform the 5 ADL 
tasks without assistance, but only 48% reported the ability to 
perform all 13 tasks without assistance (FS score = 13). The 
skewed distribution of FS scores is illustrated in Supplemental 
Figure 1; mean and median FS scores were 11.7 and 12.5, 
respectively. The distribution of FS varied widely across PDOPPS 
countries (Figure 2). Japan had the highest proportion of 
patients with FS = 13 (68%), and Thailand had the lowest 
(22%). A higher FS score (more functional independence) 
was more common in younger patients, males, nondiabetics, 
and patients who did not need assistance with their PD treat-
ments (Supplemental Figure 2). Characteristics of included 
and excluded patients for each PDOPPS country are noted in 
Supplemental Table 2.
PATIENT CHARACTERISTICS BY FS LEVEL
Table 3 shows summary statistics of patient characteristics 
by FS category. Patient age was inversely associated with FS 
score. As expected, functionally independent patients had 
indicators of better patient health status, including higher 
serum albumin and lower prevalence of several summary 
comorbid conditions. 
DIFFERENCES IN FS ACROSS COUNTRIES
Compared with PD patients in the US, PD patients in Thailand 
were more likely to have a FS score < 11, adjusting for case 
mix (adjusted OR = 10.48; 95% CI: 5.90 – 18.60) (Figure 3). 
Peritoneal dialysis patients in the UK were also more likely 
to have a FS score < 11 (adjusted OR = 3.29; 95% CI: 1.77 – 
6.08). The prevalence of a low FS score in Canada, Japan, and 
Australia/New Zealand differed little from the US (Figure 3). 
FS AND ADVERSE CLINICAL OUTCOMES
During follow-up, 313 (12%) patients died, 493 (19%) 
permanently switched to HD, and 800 (31%) either died or 
permanently switched to HD. Figure 4 shows the adjusted 
associations between the FS score and mortality, permanent 
TABLE 2 
Characteristics of Included Cohort Compared with  
Excluded Patients
Patient characteristic
Included 
patients
Excluded 
patients
Number of patients 2,593 (44%) 3,270 (56%)
Age, mean years (SD) 60.7 (14.2) 59.1 (15.4)
Male, % 58% 60%
ESRD vintage, median years (IQR) 1.7 (0.8, 3.4) 1.3 (0.6, 3.0)
Body mass index, mean kg/m2 (SD) 26.8 (6.0) 28.2 (6.4)
Laboratory data, mean (SD)
Albumin (g/dL) 3.4 (0.6) 3.4 (0.5)
Creatinine (mg/dL) 8.6 (3.7) 8.6 (3.9)
Hemoglobin (g/dL) 11.0 (1.5) 10.9 (1.6)
Phosphorus (mg/dL) 5.0 (1.4) 5.2 (1.6)
Calcium (mg/dL) 9.0 (1.2) 9.1 (1.6)
Comorbid conditions
Coronary artery disease 21% 22%
Cancer (non-skin) 11% 10%
Other cardiovascular disease 14% 13%
Cerebrovascular disease 9% 7%
Congestive heart failure 14% 13%
Diabetes 43% 49%
Gastrointestinal bleeding 2% 2%
Hypertension 91% 85%
Lung disease 5% 6%
Neurologic disease 4% 4%
Psychiatric disorder 12% 13%
Peripheral vascular disease 13% 13%
Gangrene/recurrent cellulitis 2% 2%
Amputation 2% 2%
Automated PD 62% 74%
Physical component summary score, 
mean score (SD)
39.6 (10.4) —
Mental component summary score, 
mean score (SD)
47.8 (11.0) —
CES-D Score, mean score (SD) 7.7 (5.5) —
24-hour urine volume, mean liters 
(SD)
1.0 (0.8) 0.9 (0.7)
Total Kt/V urea, mean mL/min (SD) 2.3 (0.7) 2.3 (0.7)
Require help setting up and 
performing PD
Never 70% —
Some of the time 17% —
All of the time 14% —
SD = standard deviation; ESRD = end-stage renal disease; IQR = 
interquartile range; CES-D = Center for Epidemiologic Studies 
depression, assessed by the 10-item version (26); PD = peritoneal 
dialysis.
Figure 2 — Proportion of patients in each category of functional status 
score across PDOPPS countries. PDOPPS = Peritoneal Dialysis Outcomes 
and Practice Patterns Study; ANZ = Australia and New Zealand; UK = 
United Kingdom; US = United States; FS = functional status.
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transfer to HD, and the composite outcome event. Compared 
with patients with a FS score of 13 (independent), the adjusted 
HR for mortality was 4.01 (2.44 – 6.61) for patients with a 
FS score < 8, 3.23 (2.27 – 4.60) for those with a FS score of 
8 to < 11, and 1.57 (1.13 – 2.20) for patients with a FS score 
of 11 to < 13 (p for trend for continuous FS score < 0.01). In 
contrast, there was little association between FS category and 
permanent transfer to HD. Compared with a FS score of 13, the 
adjusted HR was 0.91 (0.58 – 1.43) for a FS score < 8, 1.05 
(0.79 – 1.38) for a FS score 8 to < 11, and 1.09 (0.87 – 1.37) 
for a FS score 11 to < 13 (p for trend for continuous FS score = 
0.56). In the additional analysis where patients from Thailand 
were excluded, the adjusted HRs for all 3 outcomes were similar 
(Supplemental Figure 3).
DISCUSSION
In this study, we found that functional impairment was 
highly prevalent among PD patients in the PDOPPS. There was 
considerable variability in the prevalence of functional impair-
ment among PDOPPS countries. The prevalence of functional 
impairment was highest in Thailand and the UK and lowest 
in Japan. We also found that, when adjusting for case mix 
including comorbidities and PD treatments and stratifying by 
country, impaired FS was positively associated with all-cause 
mortality but not permanent transfer to HD.
Previous studies have identified that functional impair-
ment, measured as limitations in ADLs, is common among PD 
patients. In a cross-section of prevalent PD patients, Ulutas 
TABLE 3 
Patient Characteristics by Functional Status Score
FS score 
Patient characteristic FS<8 8≤ FS<11 11≤ FS< 13 FS=13
Number of patients 157 (6%) 364 (14%) 835 (32%) 1,237 (48%)
Age, mean years (SD) 68.8 (14.6) 65.1 (13.1) 60.6 (14.6) 58.4 (13.4)
Male, % 57% 57% 52% 64%
ESRD vintage, median years (IQR) 1.9 (1.0, 3.4) 1.8 (0.8, 3.4) 1.7 (0.7, 3.5) 1.7 (0.7, 3.5)
Body mass index, mean kg/m2 (SD) 25.2 (5.9) 27.1 (6.7) 27.5 (6.2) 26.4 (5.7)
Laboratory data, mean (SD)
Albumin (g/dL) 3.2 (0.6) 3.3 (0.6) 3.4 (0.6) 3.5 (0.5)
Creatinine (mg/dL) 7.5 (3.1) 8.0 (3.2) 8.3 (3.8) 9.1 (3.8)
Hemoglobin (g/dL) 11.0 (1.4) 10.8 (1.6) 11.0 (1.6) 11.1 (1.5)
Phosphorus (mg/dL) 4.5 (1.4) 4.8 (1.4) 5.1 (1.4) 5.1 (1.3)
Calcium (mg/dL) 8.7 (0.8) 8.9 (1.3) 9.0 (1.2) 9.0 (1.2)
Comorbid conditions
Coronary artery disease 34% 30% 21% 16%
Cancer (non-skin) 12% 13% 10% 10%
Other cardiovascular disease 27% 20% 14% 10%
Cerebrovascular disease 25% 16% 8% 6%
Congestive heart failure 26% 20% 14% 12%
Diabetes 66% 58% 41% 37%
Gastrointestinal bleeding 4% 2% 2% 2%
Hypertension 91% 91% 90% 91%
Lung disease 12% 9% 5% 3%
Neurologic disease 19% 6% 3% 2%
Psychiatric disorder 13% 16% 16% 8%
Peripheral vascular disease 23% 17% 15% 8%
Gangrene/recurrent cellulitis 4% 3% 2% 1%
Amputation 7% 4% 2% 1%
Automated PD 58% 58% 64% 62%
Physical component summary score, mean score (SD) 28.5 (8.8) 31.4 (8.5) 36.6 (9.2) 45.2 (8.4)
Mental component summary score, mean score (SD) 41.4 (12.4) 42.7 (11.4) 47.2 (10.9) 50.4 (9.8)
CES-D score, mean score (SD) 11.6 (6.1) 10.3 (5.6) 7.9 (5.1) 6.4 (5.1)
24-hour urine volume, mean liters (SD) 0.8 (0.8) 0.8 (0.8) 0.9 (0.7) 1.1 (0.8)
Total Kt/V urea, mean mL/min (SD) 2.2 (0.8) 2.2 (0.6) 2.3 (0.7) 2.3 (0.8)
Require help setting up and performing PD
Never 3% 32% 70% 88%
Some of the time 17% 35% 21% 9%
All of the time 81% 34% 9% 2%
FS = functional status; SD = standard deviation; ESRD = end-stage renal disease; IQR = interquartile range; CES-D = Center for Epidemiologic 
Studies depression, assessed by the 10-item version (38); PD = peritoneal dialysis.
Page 5 of 9 Peritoneal Dialysis International
 at W
A
SH
IN
G
TO
N
 U
N
IV
ERSITY
 on February 12, 2019
http://w
w
w
.pdiconnect.com
/
D
ow
nloaded from
 
6TENNANKORE et al. inPress PDI
and colleagues (13) found that 64% of patients 65 years 
and older had caregiver dependence in 1 or more ADLs and 
only a minority (11%) were fully independent. In a study 
conducted by Kang et al. (12) that included patients of all 
ages, 30% had an impairment in 1 or more of 4 selected ADLs. 
Ours is the first study to evaluate functional impairment 
in PD using a scale that combines ADLs and IADLs and was 
conducted across multiple centers in 7 countries. Similar to 
previous studies (12,13), functional impairment was highly 
prevalent among elderly patients in our study; however, over 
45% of young patients (aged 18 – 49) had a limitation in 1 
or more ADLs and/or IADLs, even though patients receiving 
PD are generally regarded as healthier than those receiving 
in-center HD (27). 
There are several possible reasons for the differences 
observed in the FS scores across countries. One possible reason 
is that the outcome (FS score) in this cross-sectional analysis 
may influence which ESRD patients choose or get selected for 
PD vs HD or transplantation (a form of selection bias), and the 
extent to which that happens is likely to vary among PDOPPS 
countries. For example, we speculate that the greater avail-
ability of nurse/family support for PD patients in the UK leads 
to proportionally more functionally impaired ESRD patients 
choosing PD as opposed to HD in the UK, compared with 
other PDOPPS countries. In Europe, nurse-assisted PD is most 
commonly used in France (28), yet studies from the UK have 
demonstrated the feasibility of, and improvement in, outcomes 
and patient satisfaction associated with nurse-assisted PD 
(11,16,17). While the availability of family or nurse assistance 
would be expected to increase the proportion of functionally 
impaired patients receiving PD, we did not observe differences 
in the prevalence of functional impairment between patients 
in Australia/New Zealand and Canada, compared with the US. 
This is surprising, given that there is a large proportion of 
elderly patients receiving PD in Australia/New Zealand (29), 
and assisted PD is often utilized in Canada (though this remains 
largely regionally dependent) (18). Appreciating that the avail-
ability of nurse/family assistance may be center-specific, it is 
possible that PDOPPS may have under-sampled units from these 
countries where assisted PD programs are frequently utilized. 
While nurse assistance is not common in Thailand, a country 
with a “PD first” policy, it is a requirement that patients must 
have a caregiver to help with exchanges to gain access to PD 
in Thailand (23). Furthermore, HD is not feasible for some 
patients in Thailand due to financial barriers. If the choice of 
modality is influenced by the lack of affordable HD facilities 
nearby, ESRD patients from Thailand with greater functional 
impairment may have been oversubscribed to PD relative to 
patients with similar levels of functional impairment across 
other countries. 
Not unexpectedly, functional dependence was consistently 
and monotonically associated with greater mortality. This find-
ing is similar to that of previous studies evaluating functional 
dependence in both PD and HD. In the Netherlands Cooperative 
Study on the Adequacy of Dialysis (NECOSAD) study, functional 
impairment (defined using the SF-36 physical summary score) 
(14) was associated with a higher mortality rate among PD 
patients. In a more recent study, Shum and colleagues demon-
strated an adjusted 2-fold increase in mortality rate for those 
with impairment in ADLs (15). Additionally, in the previous 
study of patients in the DOPPS using the same methods as in the 
present study, reduced functional capacity was also strongly 
associated with mortality among HD patients (10). 
Figure 3 — Crude and adjusted prevalence odds ratios of a FS score 
<11 for patients in each PDOPPS country compared with patients in 
the US. Adjustment was made for the following covariates thought 
to be risk factors for functional status (the outcome): age, sex, body 
mass index, 13 summary comorbid conditions (Table 1), prior amputa-
tion, serum albumin, hemoglobin levels, dialysis vintage, an indicator 
(yes/no) of US large dialysis organizations, and PD-specific variables 
(automated vs continuous ambulatory PD, and time transport to PD 
facility). CI = confidence interval; ANZ =  Australia and New Zealand; 
UK = United Kingdom; US = United States; PDOPPS = Peritoneal Dialysis 
Outcomes and Practice Patterns Study; FS = functional status; PD = 
peritoneal dialysis.
Figure 4 — Adjusted hazard ratio (HR; 95% CI) for the estimated effect 
of FS score on all-cause mortality, transfer to HD, and either outcome 
(whichever occurred first), comparing each FS category with FS = 13. 
Models were stratified by country, accounted for facility clustering 
using robust sandwich covariance estimators, and adjusted for age, 
sex, body mass index, 13 summary comorbid conditions (Table 1), 
prior amputation, serum albumin, hemoglobin levels, dialysis vin-
tage, an indicator (yes/no) of US large dialysis organizations, and 
PD-specific variables (automated vs continuous ambulatory PD, and 
time transport to PD facility). HD = hemodialysis; FS = functional 
status; HR = hazard ratio; CI = confidence interval; US = United States; 
PD = peritoneal dialysis.
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While functional impairment was associated with mortality, 
we did not identify an association between functional impair-
ment and permanent transfer to HD in this study. This lack of 
association may be related to the fact that 97% of patients with 
FS scores of < 8 required some assistance with their PD. Patients 
receiving assistance with PD may have similar outcomes to 
unassisted PD including peritonitis (nurse-assisted [30]) and 
hospitalization rates that are similar to in-center HD patients 
(31). Although inconsistent (32), results from studies have 
suggested that patients receiving assisted PD have similar rates 
of transfer to HD compared with those not requiring assistance 
(33,34). Another explanation underpinning the lack of associa-
tion between FS and technique failure relates to patient choice 
when faced with a decision around transferring to HD. Older 
adults with similar characteristics may perceive advantages to 
PD over in-center HD (35). These elderly patients may elect to 
forgo transfer to HD (even in settings where it may be neces-
sary) due to these perceived advantages. It has been shown 
that home dialysis patients are willing to forgo life expectancy 
in exchange for greater travel (facilitated by PD) and reduced 
hospital visits for care (36–38). 
To our knowledge, this is the first international study to 
have evaluated functional dependence among PD patients. 
Given the size and heterogeneity of the cohort, we were able 
to adjust for a number of patient characteristics (including 
comorbidities and dialysis characteristics). More importantly, 
we found an association between functional dependence and 
mortality that was consistent across countries. Finally, the 
measurement of functional dependence (using a summary 
score based on only 13 ADLs and IADLs) is easy and relatively 
simple to ascertain.
This study did have some limitations. We recognize that 
our composite FS score is based on an ad hoc procedure 
for scoring items from 2 surveys with different response 
categories (2 for basic ADLs and 3 for IADLs). However, the 
general approach of combining results from the 2 surveys 
was previously recommended by LaPlante (2010), who used 
a Guttman scale applied to data from a national household 
survey of adults (22). Furthermore, our scoring method was 
previously applied to an international cohort of HD patients in 
the DOPPS, and it was found to have good predictive validity 
(in this study as well) (10). In addition, our approach—based 
on 2 surveys known to be reliable and valid in a wide range of 
populations—provides a future opportunity for comparisons 
with the DOPPS or with other cohorts that capture ADLs and 
IADLs. As noted above, the cross-sectional comparison of FS 
score among PDOPPS countries was vulnerable to possible 
selection bias because FS may have influenced the choice or 
selection of patients for PD to a different extent across coun-
tries. We did not have available information as to the reasons 
behind the need for assistance among patients in our cohort. 
Therefore, it is possible that assistance was unnecessary for 
individual patients from certain countries and this may have 
impacted interpretation of the results. We did not have data to 
ascertain whether there were differences in the proportion of 
functionally impaired versus unimpaired patients who refused 
HD transfer even if medically indicated based on baseline FS. 
We acknowledge that there is the possibility of selection bias 
due to the fact that a large number of individuals did not 
complete a FS questionnaire. However, importantly, we found 
that: 1) known patient characteristics were largely similar 
comparing included vs excluded patients and 2) there was no 
difference in our primary outcomes of death or permanent 
transfer to HD comparing included vs excluded patients. 
Finally, while we adjusted for many covariates reflecting case 
mix, residual confounding may remain if strong predictors of 
both FS and mortality were not accounted for in this analysis.
CONCLUSION
In this international study of PD patients from the PDOPPS, 
we found that functional dependence for ADLs and IADLs was 
highly prevalent but varied across countries where the practice 
of PD may have differed with respect to policy and availability 
of caregiver assistance. Functional dependence was associated 
with an increased mortality rate but not permanent transfer 
to HD. While the latter may be associated with availability of 
assistance or patient-perceived advantages, we need to better 
understand the lack of association between functional depen-
dence and transfer to HD, and the implications of this finding 
for patient modality selection. Future studies should aim to 
identify the association between functional dependence and 
other important outcomes in PD (including peritonitis) and 
to ascertain if frailty (which includes, but is not limited to FS) 
may better predict outcomes for PD patients.
ACKNOWLEDGMENTS
Global support for the ongoing DOPPS Programs is provided without 
restriction on publications by a variety of funders. For details see 
https://www.dopps.org/AboutUs/Support.aspx.
All grants were made to Arbor Research Collaborative for Health 
and not to coauthors directly. None of the funders had any role in 
study design or collection, analysis, and interpretation of data. All 
support is provided without restrictions on publications.
Funding for PDOPPS has been provided by: National Health and 
Medical Research Council (Australia); National Institute for Health 
Research (UK); National Institute of Diabetes and Digestive and Kidney 
Diseases (USA); Patient-Centered Outcomes Research Institute (USA); 
Japanese Society of Peritoneal Dialysis; Canadian Institute for Health 
Research (Canada); Baxter International Inc. (USA); The National 
Research Council of Thailand (2558-113);  Rachadaphiseksompot 
Endorcement Fund (GCURS_59_12_30_03), Chulalongkorn University, 
Thailand; and the National Science and Technology Development 
Agency (NSTDA), Thailand.
We acknowledge and thank the following individuals for their 
contributions. 
PDOPPS Steering Committee members: David Johnson  (Australia); 
Jeffrey Perl (Canada); Mauricio Sanabria (Colombia); Hideki  Kawanishi 
(Japan); Yong-Lim Kim (South Korea); Talerngsak  Kanjanabuch 
(Thailand); Simon Davies (United Kingdom); Angelito Bernardo, 
Ron Pisoni, Bruce Robinson, Jenny Shen (United States). Additional 
PDOPPS Research Group members: Sunil Badve, Neil Boudville, Fiona 
Brown, Josephine Chow, John Collins, Rachael Morton, Scott Wilson 
Page 7 of 9 Peritoneal Dialysis International
 at W
A
SH
IN
G
TO
N
 U
N
IV
ERSITY
 on February 12, 2019
http://w
w
w
.pdiconnect.com
/
D
ow
nloaded from
 
8TENNANKORE et al. inPress PDI
(Australia); Andreas Vychytil (Austria); Wim Van Biesen (Belgium); 
Ana Figueiredo, Thyago de Moraes (Brazil); Gillian Brunier, Arsh 
Jain, Vanita Jassal, Sharon Nessim, Matthew Oliver, Valerie Price, 
Rob Quinn (Canada); Wei Fang (China); CC Szeto, Angela Wang (Hong 
Kong); Mizuya Fukasawa, Yasuhiko Ito, Munekazu Ryuzaki, Tadashi 
Tomo (Japan); Alfonso Cueto Manzano (Mexico); Mark Marshall 
(New Zealand); Susanne Ljungman (Sweden); Sarinya Boongird, 
Chanchana Boonyakrai, Areewan Cheawchanwattana, Guttiga Halue, 
Suchai Sritippayawan, Sajja Tatiyanupanwong, Kriang Tungsanga 
(Thailand); Elaine Bowes, Edwina Brown, Richard Fluck, Bak Leong 
Goh, Helen Hurst, Martin Wilkie, Graham Woodrow (United Kingdom); 
Filitsa Bender, Judith Bernardini, Dinesh Chatoth, John Crabtree, Fred 
Finkelstein, Arshia Ghaffari, Rajnish Mehrotra, Beth Piraino, Martin 
Schreiber, Isaac Teitelbaum (United States).
We would also like to thank all research nurses and coordinators 
who help to maintain the PDOPPS.
DISCLOSURES
JAS is an employee of Baxter Healthcare Corporation. The remaining 
authors have no conflicts to disclose.
REFERENCES
 1. Cook WL, Jassal SV. Functional dependencies among the elderly on hemo-
dialysis. Kidney Int 2008; 73:1289–95.
 2. Couchoud CG, Beuscart JB, Aldigier JC, Brunet PJ, Moranne OP, Registry R. 
Development of a risk stratification algorithm to improve patient-centered 
care and decision making for incident elderly patients with end-stage 
renal disease. Kidney Int 2015; 88:1178–86.
 3. DeOreo PB. Hemodialysis patient-assessed functional health status 
predicts continued survival, hospitalization, and dialysis-attendance 
compliance. Am J Kidney Dis 1997; 30:204–12.
 4. Krishnan M, Weinhandl ED, Jackson S, Gilbertson DT, Lacson E, Jr. 
Comorbidity ascertainment from the ESRD Medical Evidence Report and 
Medicare claims around dialysis initiation: a comparison using US Renal 
Data System data. Am J Kidney Dis 2015; 66:802–12.
 5. Kurella M, Covinsky KE, Collins AJ, Chertow GM. Octogenarians and nona-
genarians starting dialysis in the United States. Ann Intern Med 2007; 
146:177–83.
 6. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, 
 McCulloch CE. Functional status of elderly adults before and after initia-
tion of dialysis. N Engl J Med 2009; 361:1539–47.
 7. Thamer M, Kaufman JS, Zhang Y, Zhang Q, Cotter DJ, Bang H. Predicting 
early death among elderly dialysis patients: development and validation 
of a risk score to assist shared decision-making for dialysis initiation. Am 
J Kidney Dis 2015; 66:1024–32.
 8. Kallenberg MH, Kleinveld HA, Dekker FW, van Munster BC, Rabelink TJ, van 
Buren M, et al. Functional and cognitive impairment, frailty, and adverse 
health outcomes in older patients reaching ESRD—a systematic review. 
Clin J Am Soc Nephrol 2016; 11:1624–39.
 9. Bowling CB, Zhang R, Franch H, Huang Y, Mirk A, McClellan WM, et al. 
Underreporting of nursing home utilization on the CMS-2728 in older 
incident dialysis patients and implications for assessing mortality risk. 
BMC Nephrol 2015; 16:32.
10. Jassal SV, Karaboyas A, Comment LA, Bieber BA, Morgenstern H, Sen A, 
et al. Functional dependence and mortality in the international Dialysis 
Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2016; 
67:283–92.
11. Iyasere OU, Brown EA, Johansson L, Huson L, Smee J, Maxwell AP, et 
al. Quality of life and physical function in older patients on dialysis: a 
comparison of assisted peritoneal dialysis with hemodialysis. Clin J Am 
Soc Nephrol 2016; 11:423–30.
12. Kang SH, Do JY, Lee SY, Kim JC. Effect of dialysis modality on frailty 
phenotype, disability, and health-related quality of life in maintenance 
dialysis patients. PLOS One 2017; 12:e0176814.
13. Ulutas O, Farragher J, Chiu E, Cook WL, Jassal SV. Functional disability 
in older adults maintained on peritoneal dialysis therapy. Perit Dial Int 
2016; 36:71–8.
14. Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT. 
Predictors of poor outcome in chronic dialysis patients: the Netherlands 
Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. 
Am J Kidney Dis 2000; 35:69–79.
15. Shum CK, Tam KF, Chak WL, Chan TC, Mak YF, Chau KF. Outcomes in older 
adults with stage 5 chronic kidney disease: comparison of peritoneal 
dialysis and conservative management. J Gerontol A Biol Sci Med Sci 2014; 
69:308–14.
16. Brown N, Vardhan A. Developing an assisted automated peritoneal dialysis 
(aAPD) service—a single-centre experience. NDT Plus 2011; 4:iii16-iii8.
17. Harris SA, Lamping DL, Brown EA, Constantinovici N, North Thames Dialysis 
Study Group. Clinical outcomes and quality of life in elderly patients on 
peritoneal dialysis versus hemodialysis. Perit Dial Int 2002; 22:463–70.
18. Oliver MJ, Quinn RR, Richardson EP, Kiss AJ, Lamping DL, Manns BJ. Home 
care assistance and the utilization of peritoneal dialysis. Kidney Int 2007; 
71:673–8.
19. Perl J, Davies SJ, Lambie M, Pisoni RL, McCullough K, Johnson DW, et al. 
The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): 
unifying efforts to inform practice and improve global outcomes in peri-
toneal dialysis. Perit Dial Int 2016; 36:297–307.
20. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index 
of ADL. Gerontologist 1970; 10:20–30.
21. Lawton MP, Brody EM. Assessment of older people: self-maintaining and 
instrumental activities of daily living. Gerontologist 1969; 9:179–86.
22. LaPlante MP. The classic measure of disability in activities of daily living 
is biased by age but an expanded IADL/ADL measure is not. J Gerontol B 
Psychol Sci Soc Sci 2010; 65:720–32.
23. Chuengsaman P, Kasemsup V. PD First policy: Thailand’s response to the 
challenge of meeting the needs of patients with end-stage renal disease. 
Semin Nephrol 2017; 37:287–95.
24. Raghunathan TE, Solenberger PW, Van Hoewyk J. IVEware: Imputation 
and Variance Estimation Software User Guide. 2002. [Online.] Available 
at: ftp://ftp.isr.umich.edu/pub/src/smp/ive/ive_user.pdf.
25. Little RJA, Rubin DB. Statistical analysis with missing data. J Educ Behav 
Stat 1991; 16:150–5.
26. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depres-
sion in well older adults: evaluation of a short form of the CES-D (Center for 
Epidemiologic Studies Depression Scale). Am J Prev Med 1994; 10:77–84.
27. Kuttykrishnan S, Kalantar-Zadeh K, Arah OA, Cheung AK, Brunelli S, 
Heagerty PJ, et al. Predictors of treatment with dialysis modalities in 
observational studies for comparative effectiveness research. Nephrol 
Dial Transplant 2015; 30:1208–17.
28. Castrale C, Evans D, Verger C, Fabre E, Aguilera D, Ryckelynck JP, et al. 
Peritoneal dialysis in elderly patients: report from the French Peritoneal 
Dialysis Registry (RDPLF). Nephrol Dial Transplant 2010; 25:255–62.
29. Brown EA, Johansson L. Dialysis options for end-stage renal disease in 
older people. Nephron Clin Pract 2011; 119(Suppl 1):c10–3.
30. Benabed A, Bechade C, Ficheux M, Verger C, Lobbedez T. Effect of assis-
tance on peritonitis risk in diabetic patients treated by peritoneal dialysis: 
report from the French Language Peritoneal Dialysis Registry. Nephrol Dial 
Transplant 2016; 31:656–62.
31. Oliver MJ, Al-Jaishi AA, Dixon SN, Perl J, Jain AK, Lavoie SD, et al. Hos-
pitalization rates for patients on assisted peritoneal dialysis compared 
with in-center hemodialysis. Clin J Am Soc Nephrol 2016; 11:1606–14.
32. Cheng CH, Shu KH, Chuang YW, Huang ST, Chou MC, Chang HR. Clinical 
outcome of elderly peritoneal dialysis patients with assisted care in a 
single medical centre: a 25 year experience. Nephrology (Carlton) 2013; 
18:468–73.
33. Verger C, Ryckelynck JP, Duman M, Veniez G, Lobbedez T, Boulanger E, et al. 
French Peritoneal Dialysis Registry (RDPLF): outline and main results. 
Kidney Int Suppl 2006:S12–20.
34. Bevilacqua MU, Turnbull L, Saunders S, Er L, Chiu H, Hill P, et al. Evalua-
tion of a 12-month pilot of long-term and temporary assisted peritoneal 
dialysis. Perit Dial Int 2017; 37:307–13.
Page 8 of 9Peritoneal Dialysis International
 at W
A
SH
IN
G
TO
N
 U
N
IV
ERSITY
 on February 12, 2019
http://w
w
w
.pdiconnect.com
/
D
ow
nloaded from
 
 9
PDI inPress FUNCTIONAL STATUS, MORTALITY, AND DIALYSIS MODALITY CHANGE 
35. Brown EA, Johansson L, Farrington K, Gallagher H, Sensky T, Gordon F, 
et al. Broadening Options for Long-term Dialysis in the Elderly (BOLDE): 
differences in quality of life on peritoneal dialysis compared to haemo-
dialysis for older patients. Nephrol Dial Transplant 2010; 25:3755–63.
36. Morton RL, Snelling P, Webster AC, Rose J, Masterson R, Johnson DW, 
et al. Factors influencing patient choice of dialysis versus conservative 
care to treat end-stage kidney disease. CMAJ 2012; 184:E277–83.
37. Morton RL, Snelling P, Webster AC, Rose J, Masterson R, Johnson DW, 
et al. Dialysis modality preference of patients with CKD and family caregiv-
ers: a discrete-choice study. Am J Kidney Dis 2012; 60:102–11.
38. Lee MB, Bargman JM. Survival by dialysis modality—who cares? Clin J Am 
Soc Nephrol 2016; 11:1083–7.
Page 9 of 9 Peritoneal Dialysis International
 at W
A
SH
IN
G
TO
N
 U
N
IV
ERSITY
 on February 12, 2019
http://w
w
w
.pdiconnect.com
/
D
ow
nloaded from
 
